

Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells

Jérémy Dufloo^{1,2}, Florence Guivel-Benhassine¹, Julian Buchrieser¹, Valérie Lorin³, Ludivine Grzelak¹, Emilie Dupouy¹, Guillaume Mestrallet¹, Katia Bourdic^{5,6}, Olivier Lambotte^{5,6}, Hugo Mouquet^{3,4}, Timothée Bruel^{1,4,*} and Olivier Schwartz^{1,4,*}

¹Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris 75015, France; CNRS UMR 3569, Paris 75015, France.

²Paris Diderot University, Sorbonne Paris Cité, Paris 75013, France.

³Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris 75015, France; INSERM U1222, Paris 75015, France.

⁴Vaccine Research Institute, Créteil, France.

⁵CEA, DSV/IMETI, IDMIT; Université Paris Sud, UMR-1184; Inserm, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases.

⁶APHP, Service de Médecine Interne-Immunologie Clinique, Hôpitaux Universitaires Paris Sud, le Kremlin Bicêtre, France.

*These authors contributed equally

Correspondence to: tbruel@pasteur.fr and schwartz@pasteur.fr

Table of Contents

Appendix Table S1	2
Appendix Table S2	3
Appendix Table S3	4

Appendix Table S1. Monoclonal antibodies used in this study

Antibody	Epitope	Reference
N6	CD4 binding site	Huang 2016 Immunity
3BNC117	CD4 binding site	Scheid 2011 Science
VRC01	CD4 binding site	Wu 2010 Science
CH103	CD4 binding site	Liao 2013 Nature
b12	CD4 binding site	Burton 1991 PNAS
10-1074	V3 Glycans	Mouquet 2012 PNAS
PGT121	V3 Glycans	Walker 2011 Nature
PGT128	V3 Glycans	Walker 2011 Nature
PGDM1400	V1/V2 Glycans	Sok 2014 PNAS
PG16	V1/V2 Glycans	Walker 2009a Science
m66.6	MPER	Zhu 2011 J. Virol
10E8	MPER	Huang 2012 Nature
4E10	MPER	Buchacher 1994 AIDS Res. Hum. Retroviruses
3BC176	Gp120/41 interface	Klein 2012 J Exp Med
PGT151	Gp120/41 interface	Falkowska 2014 Immunity
8ANC195	Gp120/41 interface	Scheid 2011 Science
5-25	Gp41 immunodominant	Scheid 2009 Nature
A32	cluster A	Moore J Virol 1993
10-188	V3 crown	Mouquet 2011 Plos One
2-59	V3 crown	Scheid 2009 Nature
4-42	CoRBS	Scheid 2009 Nature
1-863	CD4 binding site	Scheid 2009 Nature
rituximab	CD20	Maloney 1997 Blood
mGO53	isotype control	Wardemann 2003 Science

Appendix Table S2. CDC IC50 of selected antibodies

Antibody	CDC IC50 ($\mu\text{g mL}^{-1}$)	Plateau (%)
N6	2.4	73
3BNC117	0.8	76
CH103	9	86
10-1074	1	85
PGT121	1.7	88
PGT128	2.6	62
10E8	16	60
5-25	0.3	30
rituximab	0.6	99

Appendix Table S3. Patients' characteristics

Patient ID	Sex	Year of diagnosis	ART duration (years)	CD4 count (per mm ³)	CD8 count (per mm ³)	Viral load (RNA copies/mL)	Viral DNA (copies/10 ⁶ leucocytes)
KBS98	Female	2005	12	586	704	<40	und.
KBS99	Male	1993	12	705	406	<40	und.
KBS100	Male	1999	17	562	1193	<40	135
KBS101	Male	2007	7	1147	895	<40	154
KBS102	Female	2000	12	897	501	<40	457
KBS103	Male	2009	8	605	1891	<40	256
KBS104	Female	2003	11	724	1008	<40	213
KBS105	Female	2005	13	813	302	<40	111
KBS106	Male	1992	10	739	1030	<40	186